Pharmafile Logo
Pharmafocus logo
Advanced Search

skin cancer

Showing 15 posts of 41 posts found.

roche

FDA approves Roche skin cancer combination

November 11, 2015
Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib

The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …

News
amgen_hq

Amgen skin cancer drug gets European approval

October 23, 2015
Research and Development Amgen, Imlygic, melanoma, skin cancer

Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …

News
MSD logo

Merck and Incyte to initiate Keytruda, epacadostat combo trial

October 15, 2015
Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer

Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …

News
keytruda3-web

MSD’s Keytruda receives green light from NICE for NHS use

October 12, 2015
Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer

The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …

News
merckincweb

NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment

October 7, 2015
Research and Development Merck, NHS, NICE, keytruda, skin cancer

The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …

News
keytruda

NICE recommends Keytruda for advanced skin cancer

September 7, 2015
Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer

NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS.  …

News
Advanced melanoma

Novartis and Merck skin cancer drugs move through pipeline

August 20, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib

Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …

News
Novartis image

FDA approves Novartis drug Odomzo

July 27, 2015
Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer

The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …

News

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News
Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News

GSK melanoma drug sees quick NICE nod

September 18, 2014
Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer

NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …

News
Novartis image

Skin cancer pill shows ‘significant’ response

February 20, 2014
Research and Development, Sales and Marketing LDE225, Novartis, bolt, skin cancer, smo

Novartis is celebrating after its investigational pill targeting the most common form of skin cancer met its primary endpoint in …

News

Skin cancer death 70% more likely in men than women

August 23, 2013
Sales and Marketing CRUK, melanoma, skin cancer

News
Zelboraf image

Eight in ten survive skin cancer

July 22, 2013
Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer

The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …

News

Melanoma: new treatments and hopes

September 19, 2011
Research and Development advanced melanoma, melanoma, skin cancer

It usually starts with a subtle change of colour or shape in an existing mole. But if left undiagnosed and …

Feature

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024